Last reviewed · How we verify
NCT05947487
CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors
Phase 1, PHASE2 trial testing CD70-targeting CAR-T cells in Solid Tumor, Adult in 30 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Chinese PLA General Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 15 July 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD70-targeting CAR-T cells — full drug profile →
Conditions studied
- Solid Tumor, Adult — all drugs for Solid Tumor, Adult →
Sponsor
Chinese PLA General Hospital
Who can join
Adults 18 to 75, any sex, with Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70 antigen positive advanced/metastatic solid tumors . In this clinical trial, at least 12 eligible patients in dose escalation period will be enrolled to receive 3 doses of CD70-CAR cell therapy according to the "3+3" principle. In dose expansion period, additional at most 21 eligible patients will be enrolled to receive CD70-CAR-T cell therapy at dose of recommended phase 2 dose(RP2D).
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
CAR-T Cell Therapy: From the Shop to Cancer Therapy.
Uscanga-Palomeque AC, Chávez-Escamilla AK, Alvizo-Báez CA, Saavedra-Alonso S, et al · · 2023 · cited 60× · PMID 37958672 · DOI 10.3390/ijms242115688 -
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.
Qin H, Zhou Z, Shi R, Mai Y, et al · · 2025 · cited 15× · PMID 40483473 · DOI 10.1186/s13045-025-01701-6 -
Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game.
Ku KS, Tang J, Chen Y, Shi Y. · · 2024 · cited 8× · PMID 38791398 · DOI 10.3390/ijms25105361 -
If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide.
Adashek JJ, Munoz JL, Kurzrock R. · · 2025 · cited 5× · PMID 39689708 · DOI 10.1016/j.medj.2024.11.003 -
Tracking cellular therapies to optimize homing against liver metastases.
Purl MC, Shick A, Canter RJ, Judge SJ. · · 2025 · cited 1× · PMID 40636106 · DOI 10.3389/fimmu.2025.1611861
Verify or expand the search:
- PubMed search for NCT05947487
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CD70-targeting CAR-T cells
Trials testing the same drug.
- NCT05948033 — CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma · Phase 1, PHASE2 · recruiting
Other recruiting trials for Solid Tumor, Adult
Currently open trials in the same condition.
- NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
- NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
- NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
- NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
- NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
Other Chinese PLA General Hospital trials
Trials by the same sponsor.
- NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
- NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
- NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
- NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
- NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05947487 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
- Last refreshed: 17 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05947487.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing